Researchers at Georgia State University and collaborating institutions have developed a single therapeutic antibody that neutralizes all three highly pathogenic human coronaviruses — SARS-CoV, SARS-CoV-2 and MERS-CoV — and protected animals from infection, according to a study published in the journal ACS Nano.
The work, led by scientists in Georgia State's Institute for Biomedical Sciences, addresses a persistent gap: although these three coronaviruses continue to cause outbreaks or pose pandemic risks, no existing treatment works against all of them simultaneously.
The team built what is known as a bispecific nanobody — a tiny antibody fragment roughly one-tenth the size of a conventional antibody. Nanobodies are derived from the heavy-chain-only antibodies found in camelids, and they offer several advantages: strong binding affinity, high stability across a range of temperatures and pH levels, low production costs, and the ability to reach parts of viral proteins that larger antibodies cannot access.
From immunized phage display libraries, the researchers first identified two individual nanobodies. One, called 3B11, bound to the receptor-binding domains (RBDs) of both SARS-CoV and SARS-CoV-2, neutralizing diverse strains and variants of those viruses. The other, 1C11, neutralized all tested strains of MERS-CoV. An Fc-fused version of 1C11 — in which the nanobody was attached to a segment of a human antibody — showed substantially enhanced potency.
Using cryo-electron microscopy, computational modeling and epitope-mapping techniques, the team determined the precise sites on the viral spike proteins that these nanobodies recognize, helping explain their antiviral mechanism: they block the interaction between the viral RBDs and the receptors that the viruses use to enter human cells.
The researchers then combined the two nanobodies into a single bispecific molecule, designated 3B11−1C11-Fc. According to the study, this construct neutralized all tested SARS-CoV, SARS-CoV-2 and MERS-CoV viral strains, remained stable across a wide range of pH and temperature conditions, and could be produced at high yield in mammalian cells — a feature that could support large-scale manufacturing.
In mouse models, a single dose of the bispecific nanobody significantly reduced viral loads and protected the animals from infection by all three coronaviruses. Most treated animals showed no weight loss or severe clinical symptoms.
"Our goal was to develop a single therapeutic that could address all three highly pathogenic coronaviruses," said Lanying Du, a Distinguished University Professor in the Institute for Biomedical Sciences at Georgia State and a corresponding author of the study, as reported by Georgia State News. "This bispecific nanobody binds and neutralizes SARS-CoV, SARS-CoV-2 and MERS-CoV, and protected mice against all three highly pathogenic human coronaviruses, showing its promise for further therapeutic development."
The study was funded by the National Institute of Allergy and Infectious Diseases and the National Institute of General Medical Sciences, both part of the National Institutes of Health.
First author Shengnan Qian and co-first authors Abhijeet Roy, Yu Li and Abhishek K. Verma contributed to the work, along with co-corresponding authors Yang Yang of Iowa State University and Stanley Perlman of the University of Iowa. Additional co-authors from Georgia State, Iowa State, the University of Iowa, Johns Hopkins University School of Medicine, the University of Minnesota Medical School and the Wistar Institute also participated.
For university students studying biomedical sciences, immunology or virology, the research illustrates how nanobody technology — already used in some approved therapies — could be engineered into a broad-spectrum tool against viral families that keep emerging. The approach also highlights the growing role of structural biology techniques such as cryo-electron microscopy in rational drug design.
The findings are still at the preclinical stage; human trials would be needed before any therapeutic could reach patients. But the study provides a proof of concept that a single molecule can neutralize three distinct, highly pathogenic coronaviruses, potentially offering a faster route to treatments for future coronavirus outbreaks.